What we do
What we do
Advice on drug developments
The identification and selection of a development candidate is a complex process that is often justified by specificity and effectiveness in an in vitro or animal model. But the estimation of oral absorption, the “first-pass effect”, the metabolic clearance and the presumed cascade of metabolism are also among the selection parameters. Since reliable data is often lacking, experience plays an important role. After selecting a candidate, an exciting interaction between preclinical safety testing and tolerability in humans begins. A lot of development time can be saved through smooth planning of toxicology and clinical pharmacology as well as through a confident handling of CRO’s and EC.
The common basis for the development projects is the know-how about the estrogen 8-prenylnaringenin from hops. My know-how extends from synthesis, special pharmacology, toxicology, biotransformation, and clinical phase I (oral) to self-experiments and a clinical observation study for SKIN-PIN-FORTE. Of course, we will use the tolerance data for 8-PN over the centuries of beer consumption.
KAIROSmetics UG currently owns > 200 g of micronized substance. This amount of substance is sufficient for a series of in vitro studies and also for limited pharmaceutical experiments with the aim of establishing application patents. The first controlled clinical trials with proof of effectiveness could also be carried out without delay.